CervoMed Announced Neflamapimod Selected For Inclusion In UK EXPERTS-ALS Platform For Amyotrophic Lateral Sclerosis Based On Targeted Mechanism, Demonstrated Clinical Activity In Neurodegenerative Diseases, And Translational Data In ALS Relevant N...

CervoMed Inc. +2.49% Post

CervoMed Inc.

CRVO

4.11

4.11

+2.49%

0.00% Post
CervoMed Announced Neflamapimod Selected For Inclusion In UK EXPERTS-ALS Platform For Amyotrophic Lateral Sclerosis Based On Targeted Mechanism, Demonstrated Clinical Activity In Neurodegenerative Diseases, And Translational Data In ALS Relevant Neurotoxicity Models
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via